New York is currently home to 4435 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
Recruiting
This is a multi-center, open-label, Phase 0 substudy designed to evaluate the localized pharmacodynamics (PD) of rilvegostomig, volrustomig, sabestomig, and AZD9592 within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in patients presenting with Head and Neck Squamous Cell Carcinoma (HNSCC) with a surface accessible lesion, who are scheduled for tumor and/or regional node dissection as part of their standard treatment. PD effects du... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Head and Neck Squamous Cell Carcinoma
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Recruiting
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/16/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Advanced or Metastatic NRAS-mutant Melanoma
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
Recruiting
This phase I/II trial studies the side effects of interstitial photodynamic therapy following palliative radiotherapy and how well it works in treating patients with inoperable malignant central airway obstruction. Patients who have advanced stage cancer tumors in the lung can often have the breathing passages to the lung partially or completely blocked. These tumors could be due to lung cancer or other cancers (e.g., renal, breast, kidney, etc.) that spread to the lung. This blockage puts the p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Malignant Solid Neoplasm
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Recruiting
This phase I trial tests the change in androgen receptor sensitivity, side effects and effectiveness of bipolar androgen therapy, using testosterone, in patients with castration resistant prostate cancer that has spread to other places is the body (metastatic). Bipolar androgen therapy is the regulation of testosterone between castration levels (lower than what would be normally present) and supraphysiological levels (amounts greater than normally found in the body). This may suppress cancer cel... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
International Registry of Intra-arterial and Endosaccular Flow Diverters (IRF)
Recruiting
This multicenter retrospective cohort study aims to evaluate and compare the technical performance, safety, and clinical outcomes of intracranial aneurysms treated with flow diverter stents and endosaccular flow disruptors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Montefiore Medical Center Department of Neurosurgery, Bronx, New York
Conditions: Intracranial Aneurysm
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Recruiting
This is a parallel group, Phase 3, multinational, multicenter, randomized, double blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participant... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/16/2025
Locations: CHEAR Center- Site Number : 8401123, Bronx, New York
Conditions: Dermatitis Atopic
Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3
Recruiting
The current study will assess the acceptability and feasibility of the CareMeds intervention with a larger sample (N = 100) across multiple sites in Buffalo, NY, and Atlanta, GA.
Gender:
ALL
Ages:
Between 3 years and 9 years
Trial Updated:
01/16/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Acute Lymphoblastic Leukemia, Pediatric
Cleaner Air for Lower Cardiometabolic Risk
Recruiting
The purpose of this interventional sham-controlled pilot study is to study the effects of using portable air cleaners (PACs) in outpatient adults with prediabetes. The primary aims are to determine the effect PAC's have on glycemic variability and the concentrations of circulating biomarkers of inflammation.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/16/2025
Locations: NYU Langone Medical Center, New York, New York
Conditions: PreDiabetes
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
Recruiting
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ZL-1218 as a single agent and as combination therapy in subjects with advanced solid tumor malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Zai Lab Site 2002, New York, New York
Conditions: Malignant Solid Tumor
A Clinical Study of Bemcentinib with Standard of Care Chemoimmunotherapy in Untreated Advanced/metastatic Non-small Cell Lung Cancer Patients with a Mutation in the STK11 Gene
Recruiting
The primary purpose of this study is to determine the safety and tolerability of the combination of bemcentinib with chemo-immunotherapy (CIT) to identify the recommended phase 2 dose (RP2D) when administered as first line (1L) treatment in participants with locally advanced (Stage IIIb/IIIC) or metastatic (Stage IV) non-squamous NSCLC with no actionable mutations and to determine the anti-tumor activity of the combination of bemcentinib with CIT when administered as 1L treatment in participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Carcinoma, Non-Small-Cell Lung
Hydrogen-rich Water and Treatment of Mucositis Caused by Radiation Therapy in Head and Neck Cancer Patients
Recruiting
This study explores the effects of hydrogen-rich water on alleviating the radiation-induced acute mucositis in head and neck cancer patients
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Stony Brook Cancer Center, Stony Brook, New York
Conditions: Mucositis Oral
A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors
Recruiting
This is a Phase 1/2, multicenter, open label, first in human (FIH) study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York
Conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor